Drug intelligence / Profile preview

SYNT-203

Development stage: Unknown
Lead developer: Syntis Bio
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

SYNT-203 is an orally administered, gastrointestinal-stable enzyme replacement therapy being developed for the treatment of maple syrup urine disease (MSUD). The drug consists of a leucine decarboxylase enzyme engineered for stability and performance in the digestive tract. Its mechanism involves breaking down and eliminating excess leucine in the gut to control circulating leucine levels, thereby addressing the metabolic defect underlying MSUD. The therapy is designed to be gut-restricted, minimizing systemic exposure and potential side effects. Developed using Syntis Bio’s DIGEST platform technology, SYNT-203 aims to extend intestinal activity and enable continuous leucine elimination with simplified dosing regimens. Originally developed by Codexis as CDX-62103, it was acquired by Syntis Bio in April 2024[1][2][3][4][8].

Other names: SYNT 203SYNT203SYNT-203

Beyond the preview

Go deeper on SYNT-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYNT-203.

Explore the full profile